Category: Fellows Posters
Purpose: Development of immune checkpoint inhibitors (ICPis) has transformed cancer therapy including lung cancer. Non-small cell lung cancer (NSCLC) accounts for 85% of all lung cancer cases. Recently, the use of ICPis in NSCLC has shown prolonged progression-free survival (PFS) and overall survival (OS) in patients with programmed death-ligand 1 expression. Despite the clinical benefits, ICPis are associated with various immune-related adverse events (irAEs). This study aims to assess irAEs and their correlation with response to ICPis in patients diagnosed with NSCLC. Additionally, this study will determine if the incidence and type of immune-related adverse events vary among different race/ethnic groups.
Methods: This is a retrospective chart review of patients diagnosed with NSCLC and treated with ICPis at Memorial Cancer Institute from July 2014 to present. Data will be collected from the system’s electronic medical record and 150 patient records are expected to be reviewed. Patients who are 18 years and older, diagnosed with stage IIIB or IV NSCLC with or without driver mutations will be included in this study. The following data will be collected: gender, race (black, white or Asian descent) and ethnicity (Hispanic or non-Hispanic), age, smoking status, PD-L1 expression percentage, presence of driver mutations, chemotherapy regimen, immunotherapy agent used, occurrence and type of immune-related adverse event, medications used to manage any immune-related adverse events, progression free survival (PFS), and overall survival (OS).